Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zivo Bioscience Inc. Warrants (ZIVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: ZIVOW (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.55% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.33M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.12 - 2.38 | Updated Date 05/26/2025 |
52 Weeks Range 0.12 - 2.38 | Updated Date 05/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13411.4% |
Management Effectiveness
Return on Assets (TTM) -948.38% | Return on Equity (TTM) -3956.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1365620 |
Shares Outstanding - | Shares Floating 1365620 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zivo Bioscience Inc. Warrants
Company Overview
History and Background
Zivo Bioscience, Inc. focuses on developing therapies derived from algal sources. The warrants are derivative securities granting the holder the right to purchase Zivo common stock at a specified price.
Core Business Areas
- Biopharmaceutical Development: Zivo focuses on developing algal-based compounds for human and animal health applications. Current focus on coccidiosis in poultry and a potential human inflammatory disease treatment.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The organizational structure is typical of a small, development-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- ZIVO Algal Products (Developmental): Zivo's primary offering is the development of novel algal-based compounds. These are still in clinical/pre-clinical development, so there is currently no market share or revenue. Competitors include traditional pharmaceutical companies and other biotech firms focused on inflammatory diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. Regulatory approval processes are stringent and lengthy.
Positioning
Zivo Bioscience Inc. Warrants is a small-cap company focused on niche areas within the biopharmaceutical sector. Its competitive advantage lies in its proprietary algal-based technology.
Total Addressable Market (TAM)
The TAM for human inflammatory diseases and animal health products is estimated to be in the billions of dollars. Zivo is positioned to capture a small segment of this TAM pending successful product development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary algal-based technology platform
- Potential for novel therapies in unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- High dependence on successful clinical trials
- Lack of commercialized products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Potential for breakthrough therapies
Threats
- Failure to obtain regulatory approvals
- Competition from established pharmaceutical companies
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- MRK
- LLY
- NVO
Competitive Landscape
Zivo Bioscience Inc. Warrants faces intense competition from established pharmaceutical companies with significantly greater resources. Its success hinges on its unique technology and niche market focus.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue.
Future Projections: Future growth depends on the successful development and commercialization of its algal-based therapies. Analyst estimates may vary widely.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials and seeking partnerships.
Summary
Zivo Bioscience is a development-stage biopharmaceutical company with a proprietary algal-based technology platform. While it holds promise for novel therapies and has an experienced team, the company faces significant financial and regulatory challenges. Success depends on favorable clinical trial results and strategic partnerships. They need to look out for large company competition and funding issues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zivo Bioscience Inc. Warrants
Exchange NASDAQ | Headquaters Troy, MI, United States | ||
IPO Launch date 2021-05-28 | President, CEO & Chairman of the Board Mr. John Bernard Payne | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zivobioscience.com |
Full time employees 7 | Website https://www.zivobioscience.com | ||
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.